Carter's Q3 Adjusted EPS Up 39%, but FY26 EPS Guidance Points to a Decline
CRI sits 20% above its 52-week low of $27.86.
Summary
Carter's beat on Q3 profitability with adjusted EPS of $1.03, up 39%, but guided full-year adjusted EPS to $3.05-$3.23, a decline from $3.47, while announcing a broad leadership restructuring.
Key Events · Earnings and Guidance · CRI
-
Q3 Adjusted EPS Up 39%
Adjusted diluted EPS was $1.03 versus $0.74 a year ago; GAAP diluted EPS was $1.00 versus $0.32. Adjusted operating income rose 44.6% to $56.9M on net sales of $752.5M, down 0.7%.
-
FY26 EPS Guidance Implies Decline
Full-year adjusted diluted EPS is guided to $3.05-$3.23 versus $3.47 in fiscal 2025, a high-single to low-double digit decline, on net sales of $2.91B-$2.93B and adjusted operating income of $178M-$187M.
-
Q4 Outlook Below Prior Year
Fourth-quarter guidance is $860M-$880M in net sales, $74M-$83M in adjusted operating income and $1.37-$1.55 in adjusted EPS, against $1.90 in Q4 fiscal 2025 (a 14-week quarter).
-
Leadership Structure Overhauled
Carter's named Maria Gemzell Chief Product Officer (joining early 2027), appointed Allison Peterson Chief Commercial Officer, and began a search for a standalone COO; Richard Westenberger steps down as COO but remains CFO.
Analysis · CRI · Manufacturing
Carter's delivered a strong margin quarter — adjusted operating income rose 44.6% to $56.9M and adjusted EPS jumped 39% to $1.03 — but the full-year outlook calls for adjusted EPS of $3.05-$3.23 versus $3.47 last year, a high-single to low-double digit decline. Sales are guided to $2.91B-$2.93B, roughly flat to slightly up on a 52-week basis against a 53-week prior year. The market has to weigh improving profitability against a softer revenue and earnings trajectory, and the simultaneous leadership overhaul — a new Chief Product Officer, a combined Chief Commercial Officer role, and a COO transition — adds execution risk to the turnaround narrative under new CEO Sharon Price John.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRI was trading at $33.38 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $27.86 to $44.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.